ARBITRIO, MARIAMENA
 Distribuzione geografica
Continente #
AS - Asia 2.167
NA - Nord America 1.636
EU - Europa 712
SA - Sud America 417
Continente sconosciuto - Info sul continente non disponibili 305
AF - Africa 39
OC - Oceania 2
Totale 5.278
Nazione #
US - Stati Uniti d'America 1.565
SG - Singapore 879
CN - Cina 472
IT - Italia 370
BR - Brasile 328
HK - Hong Kong 226
VN - Vietnam 207
FR - Francia 122
KR - Corea 87
BD - Bangladesh 86
JP - Giappone 61
NL - Olanda 47
FI - Finlandia 44
GB - Regno Unito 33
IN - India 32
CA - Canada 28
DE - Germania 24
AR - Argentina 20
EC - Ecuador 19
ID - Indonesia 17
CO - Colombia 16
MX - Messico 16
IL - Israele 13
SA - Arabia Saudita 11
VE - Venezuela 11
PK - Pakistan 10
AT - Austria 9
RU - Federazione Russa 9
TR - Turchia 9
ZA - Sudafrica 9
PH - Filippine 8
CL - Cile 7
IQ - Iraq 7
ES - Italia 6
JM - Giamaica 6
PL - Polonia 6
SE - Svezia 6
EG - Egitto 5
IE - Irlanda 5
NP - Nepal 5
PE - Perù 5
PY - Paraguay 5
TH - Thailandia 5
TN - Tunisia 5
UA - Ucraina 5
UY - Uruguay 5
UZ - Uzbekistan 5
BH - Bahrain 4
HN - Honduras 4
KE - Kenya 4
MA - Marocco 4
AZ - Azerbaigian 3
CH - Svizzera 3
CR - Costa Rica 3
DZ - Algeria 3
GT - Guatemala 3
HU - Ungheria 3
JO - Giordania 3
LT - Lituania 3
LV - Lettonia 3
MY - Malesia 3
OM - Oman 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BE - Belgio 2
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
NI - Nicaragua 2
RS - Serbia 2
SN - Senegal 2
AL - Albania 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GN - Guinea 1
GR - Grecia 1
HR - Croazia 1
IM - Isola di Man 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MG - Madagascar 1
MK - Macedonia 1
MN - Mongolia 1
PA - Panama 1
PR - Porto Rico 1
RE - Reunion 1
SC - Seychelles 1
SI - Slovenia 1
SV - El Salvador 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.974
Città #
Santa Clara 568
Singapore 500
Hong Kong 220
Hefei 213
San Jose 165
Ashburn 119
Lauterbourg 96
Seoul 85
Ho Chi Minh City 78
Beijing 69
Hanoi 48
Los Angeles 43
Tokyo 43
New York 39
Dallas 38
Council Bluffs 33
Milan 27
Lappeenranta 26
São Paulo 23
Rome 21
Helsinki 17
Buffalo 14
Brooklyn 13
Chicago 13
Benevento 12
Naples 12
Atlanta 11
Minamishinagawa 11
Hải Dương 10
Orem 10
Rio de Janeiro 10
Biên Hòa 9
Falkenstein 8
Montreal 8
Phoenix 8
San Nicola Manfredi 8
Amsterdam 7
Baghdad 7
Belo Horizonte 7
Bologna 7
Brasília 7
Miami 7
Palermo 7
Bari 6
Bengaluru 6
Dhaka 6
Newark 6
Portland 6
Quito 6
Stockholm 6
Vienna 6
Boardman 5
Cagliari 5
Da Nang 5
Detroit 5
Goiânia 5
Guayaquil 5
Haiphong 5
Jeddah 5
Karachi 5
Lima 5
Mexico City 5
Philadelphia 5
Tashkent 5
The Bronx 5
Campos dos Goytacazes 4
Caracas 4
Catania 4
Curitiba 4
Dublin 4
Elk Grove Village 4
Figino 4
Frankfurt am Main 4
Houston 4
Hyderabad 4
Irmo 4
Manchester 4
Montevideo 4
Nairobi 4
Pingdingshan 4
Rende 4
San Antonio 4
Santa Venerina 4
Thái Bình 4
Toritto 4
Toronto 4
Tunis 4
Vallefiorita 4
Warsaw 4
Amman 3
Baku 3
Bangkok 3
Betim 3
Blumenau 3
Bogotá 3
Boston 3
Brescia 3
Cairo 3
Carpi 3
Catanzaro 3
Totale 2.924
Nome #
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis 123
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 116
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 93
Mmrf-commpass data integration and analysis for identifying prognostic markers 91
Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity 90
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 88
The First-In-Class Anti-AXL×CD3? Pronectin(TM)-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 85
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 84
DMET-analyzer: automatic analysis of Affymetrix DMET data 81
L-NAME prevents PGE2 accumulation but not enhancement of COX-2 expression in the brain of rats treated with lithium and tacrine 79
Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents 78
PROTECTIVE EFFECTS OF BERGAMOT OIL EXTRACT ON MORPHINE TOLERANCE DESCRIBED BY HPLC/FLUORESCENCE ASSAY 77
A Novel Bispecific T-Cell Engager (CD1a x CD3") BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 75
APrognostic and Carboplatin Response Predictive Model in Ovarian CancerA Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 73
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 73
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 72
Autophagy and neuroprotection in astrocytes exposed to 6-hydroxydopamine is negatively regulated by NQO2: relevance to Parkinson's disease. 71
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 71
Inhibition of miR-21 as an innovative approach, to target Bone Disease, related to Th17 cells in Multiple Myeloma 70
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 70
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 68
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates (vol 5, e326, 2016) 67
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity. 67
DMET(TM) Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine 66
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 64
Pharmacogenomics: Challenges and Future 61
Microarray Data Analysis Protocol 61
Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and LH/LH mice). 60
Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation 60
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study 59
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 59
Effetti biologici e comportamentali dopo esposizione prenatale ad etanolo nel ratto 58
ROLE OF MAP KINASES IN FETAL ALCHOOL SYNDROME 58
Melatonin improves behavioural response on forced swimming test and decrease neuronal damage after paraquat treatment in two mice strains 57
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 56
Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future 56
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: a systematic review 55
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease 54
Ethical Perspectives on Pharmacogenomic Profiling 52
ELECTROCORTICOGRAPHIC EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA, ECSTASY) ARE POTENTIATED BY ACOUSTIC STIMULATION IN RATS 51
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 51
Precision Oncology: Present Status and Perspectives 49
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 47
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 46
The protective effect of olive oil phenols hydroxytyrosol and oleuropein on morphine tolerance. 46
Preprocessing and Analysis of DMET Data for Pharmacogenomics 45
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma 45
Polymorphisms in ADME genes as potential predictor of multiple myeloma susceptibility 44
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 43
Prenatal ethanol exposure effects on map-kinases pathway in a genetic model of absence epilepsy: the WAG/Rij rat. 43
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 43
Experimental treatment of multiple myeloma in the era of precision medicine 42
Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice 42
Integration of DNA Microarray with Clinical and Genomic Data 41
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 40
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis 40
Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS 40
miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy 39
Ethanol effects on map-kinases pathway in an experimental model of fethal alcohol sindrome (FAS). 39
miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma 39
Esposizione al forced swimming test (FST) di Porsolt di topi trattati con il neurolettico atipico quetiapina fumarato. 39
Paraquat, MPTP, MPDP and MPP+ inibithion of acetylcholine and butyrylcholine esterases: a comparison to tacrine. 39
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. 37
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. 36
Genetic variants associated with gastrointestinal symptoms in Fabry disease 36
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 36
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 36
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes. 35
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study 35
Electrocorticographic effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are potentiated by acoustic stimulation in rats 35
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 35
Effetti del neurolettico atipico quetiapina fumarato in topi KO iNOS dopo esposizione al forced swimming test (FST) di Porsolt. 35
Behavioural despair in topi Kn NOSi dopo esposizione al Forced Swimming test (FST) di Porsolt 34
Systemic administration of idebenone-cyclodextrin complex protects against paraquat-induced neuronal death in the hippocampus of rat 34
Role of dopaminergic mechanism in the regulation of immune system. 33
Effetti comportamentali della sindrome alcolica fetale in due ceppi di ratto. 32
Evidence that CRH microinfused into the Locus Coeruleus impairs immune response in rats 31
Mouse models of multiple myeloma: Technologic platforms and perspectives 31
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 31
Identification of polymorphic variants correlated to taxanes neurotoxicity in breast cancer patients by Dmet microarray platform. 31
Evidence that CRH microinfused into the locus coeruleus decreases cell-mediated immune response in rats. 30
CISPLATINUM SENSITIVITY OF BRCA1-MUTATED HCC1937 BREAST CANCER CELLS IS LINKED TO IMPAIRMENT OF NOTCH SIGNALING AND IS INCREASED BY GAMMA-SECRETASE INHIBITORS 30
Inhibition of NK activity by CRH microinfused into the Locus Coeruleus in rats 30
Modulazione della produzione di citochine in topi vecchi. 30
Chronic maternal ethanol administration affects the developmentt of pentylenetetrazole kindling 30
miR-22 suppresses DNA ligase III addiction in multiple myeloma 29
Effetto di citochine sulla produzione di IL-2, IL-4 e IFN-? nella senescenza 28
Dopamine D1 receptors in amigdala enhance immune mechanism in rats. 28
Modulazione della risposta comportamentale dopo trattamento con neurolettici atipici in topi ICR e KO NOSi. 28
Cisplatinum Sensitivity of BRCA1-Mutated HCC1937 Breast Cancer Cells Is Linked to Impairment of Notch Signaling and Is Increased by ?-Secretase Inhibitors 28
Crhonic administration of paraquat produces immunosuppression of T lymphocytes and astrocytosis in rats 28
EFFECTS OF ATYPICAL NEUROLEPTIC QUETIAPINE FUMARATE TREATMENT IN KO iNOS MICE AFTER EXPOSITION TO THE PORSOLT FORCED SWIMMING TEST 28
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 28
Regulation of cytokine production in aging mice. 28
Chronic maternal ethanol administration in rat: morphological and histochemical findings in peripheral nerve 27
A reappraisal of the role of the various opioid receptor subtypes in cell-mediated immunity 27
Evidence for an involvement of dopamine D1 receptors in the limbic system in the control of immune 27
Effects of neuroleptics treatment with quetiapine fumarate on immobility time of mice in the Porsolt forced swimming test 27
In vivo anti-myeloma activity and modulation of gene expression profile induced by Valproic Acid, a histone deacetylase inhibitor 26
Melatonin improve behavioural response on forced swimming test (FST) after paraquat treatment in two mice strains. 26
Totale 4.967
Categoria #
all - tutte 17.319
article - articoli 10.928
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.199
Totale 29.446


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20246 0 0 0 0 0 0 0 0 4 0 0 2
2024/20252.094 21 6 127 57 534 74 125 229 100 62 394 365
2025/20262.696 113 259 235 424 419 110 418 135 154 139 183 107
2026/2027482 137 135 210 0 0 0 0 0 0 0 0 0
Totale 5.278